Pei‐Jer Chen

57.8k total citations · 6 hit papers
836 papers, 38.4k citations indexed

About

Pei‐Jer Chen is a scholar working on Epidemiology, Hepatology and Molecular Biology. According to data from OpenAlex, Pei‐Jer Chen has authored 836 papers receiving a total of 38.4k indexed citations (citations by other indexed papers that have themselves been cited), including 503 papers in Epidemiology, 497 papers in Hepatology and 127 papers in Molecular Biology. Recurrent topics in Pei‐Jer Chen's work include Hepatitis B Virus Studies (425 papers), Hepatitis C virus research (420 papers) and Liver Disease Diagnosis and Treatment (318 papers). Pei‐Jer Chen is often cited by papers focused on Hepatitis B Virus Studies (425 papers), Hepatitis C virus research (420 papers) and Liver Disease Diagnosis and Treatment (318 papers). Pei‐Jer Chen collaborates with scholars based in Taiwan, United States and China. Pei‐Jer Chen's co-authors include Ding‐Shinn Chen, Jia‐Horng Kao, Chun‐Jen Liu, Ming–Yang Lai, Shiou‐Hwei Yeh, Chen‐Hua Liu, Kuen‐Feng Chen, Chi‐Ling Chen, Ann‐Lii Cheng and Tung‐Hung Su and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Pei‐Jer Chen

813 papers receiving 37.5k citations

Hit Papers

Hepatitis B e Antigen and... 2000 2026 2008 2017 2002 2015 2000 2014 2011 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma
    2002 926 citations Hwai‐I Yang, Sheng‐Nan Lu et al. profile →
  2. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
    2015 879 citations Pei‐Jer Chen, Morris Sherman et al. profile →
  3. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B
    2000 784 citations Jia‐Horng Kao, Pei‐Jer Chen et al. Gastroenterology profile →
  4. Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
    2014 465 citations Pei‐Jer Chen et al. Journal of Clinical Oncology profile →
  5. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score
    2011 457 citations Hwai‐I Yang, Kwang‐Hyub Han et al. profile →
  6. High Levels of Hepatitis B Surface Antigen Increase Risk of Hepatocellular Carcinoma in Patients With Low HBV Load
    2012 415 citations Tai‐Chung Tseng, Chun‐Jen Liu et al. Gastroenterology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Pei‐Jer Chen 23.3k 22.6k 6.8k 3.7k 3.0k 836 38.4k
Stefan Zeuzem 32.8k 1.4× 34.2k 1.5× 5.3k 0.8× 5.0k 1.4× 2.1k 0.7× 1.0k 47.0k
Christian Bréchot 12.9k 0.6× 11.7k 0.5× 5.4k 0.8× 2.1k 0.6× 1.7k 0.6× 342 22.6k
Dieter Häussinger 14.3k 0.6× 14.9k 0.7× 10.3k 1.5× 2.2k 0.6× 3.0k 1.0× 829 40.2k
Kazuaki Chayama 15.7k 0.7× 14.9k 0.7× 7.5k 1.1× 2.0k 0.5× 3.0k 1.0× 1.4k 45.3k
Zachary Goodman 33.3k 1.4× 31.0k 1.4× 3.0k 0.4× 3.4k 0.9× 1.2k 0.4× 299 42.1k
Christian Trautwein 15.3k 0.7× 12.9k 0.6× 9.7k 1.4× 1.4k 0.4× 6.9k 2.3× 709 36.2k
William M. Lee 16.2k 0.7× 19.4k 0.9× 3.5k 0.5× 1.5k 0.4× 1.5k 0.5× 385 32.7k
Frank Tacke 22.5k 1.0× 16.5k 0.7× 9.2k 1.3× 1.7k 0.5× 11.4k 3.8× 708 45.5k
Masao Omata 17.7k 0.8× 19.5k 0.9× 10.0k 1.5× 2.0k 0.6× 3.7k 1.3× 1.1k 50.7k
Jacob George 16.5k 0.7× 9.1k 0.4× 5.6k 0.8× 703 0.2× 4.8k 1.6× 623 30.4k

Countries citing papers authored by Pei‐Jer Chen

Since Specialization
Citations

This map shows the geographic impact of Pei‐Jer Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pei‐Jer Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pei‐Jer Chen more than expected).

Fields of papers citing papers by Pei‐Jer Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pei‐Jer Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pei‐Jer Chen. The network helps show where Pei‐Jer Chen may publish in the future.

Co-authorship network of co-authors of Pei‐Jer Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Pei‐Jer Chen. A scholar is included among the top collaborators of Pei‐Jer Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pei‐Jer Chen. Pei‐Jer Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Chen, Pei‐Jer. (2024). Challenges for hepatitis B control in Asia‐Pacific areas: Consolidating vaccination and rolling‐out antiviral therapies. Journal of Gastroenterology and Hepatology. 39(6). 1033–1039.
3.
Huang, Yi‐Hsiang, Kun‐Yun Yeh, Pei‐Jer Chen, et al.. (2024). CVM-1118: An oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—A phase IIa study.. Journal of Clinical Oncology. 42(23_suppl). 92–92. 1 indexed citations
4.
Chen, Pei‐Jer, Mian Liu, Dengjie Ouyang, et al.. (2023). Age-based factors modulating the required thyroxine dose to achieve thyrotropin suppression in intermediate-and high-risk papillary thyroid cancer. Frontiers in Endocrinology. 14. 1126592–1126592. 3 indexed citations
5.
Tseng, Tai‐Chung, Chun‐Jen Liu, Chun‐Ming Hong, et al.. (2023). Low Hepatitis B Core–Related Antigen Levels Correlate Higher Spontaneous Seroclearance of Hepatitis B Surface Antigen in Chronic Hepatitis B Patients With High Hepatitis B Surface Antigen Levels. Gastroenterology. 164(4). 669–679.e6. 13 indexed citations
6.
Cheng, Pin‐Nan, Hsing‐Tao Kuo, Pei‐Lun Lee, et al.. (2023). Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B. Alimentary Pharmacology & Therapeutics. 59(2). 230–238. 8 indexed citations
7.
Yeh, Shiou‐Hwei, et al.. (2023). Hepatitis B Virus DNA Integration Drives Carcinogenesis and Provides a New Biomarker for HBV-related HCC. Cellular and Molecular Gastroenterology and Hepatology. 15(4). 921–929. 44 indexed citations
8.
Lin, Zhong‐Zhe, Mickey C.‐T. Hu, Chiun Hsu, et al.. (2023). Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma. Cancer Letters. 556. 216063–216063. 7 indexed citations
9.
Khan, Shahrukh, Pei‐Jer Chen, LA Crocombe, et al.. (2023). Self‐reported oral health status, edentulism and all‐cause mortality risk in 12 809 Australian older adults: a prospective cohort study. Australian Dental Journal. 69(2). 82–92. 3 indexed citations
10.
11.
Yeh, Kun‐Huei, Yung‐Ming Jeng, Li‐Ling Wu, et al.. (2020). Complement C1q mediates the expansion of periportal hepatic progenitor cells in senescence-associated inflammatory liver. Proceedings of the National Academy of Sciences. 117(12). 6717–6725. 13 indexed citations
12.
Hu, Hui-Han, Jessica Liu, Chin–Lan Jen, et al.. (2018). Level of Hepatitis B (HB) Core Antibody Associates With Seroclearance of HBV DNA and HB Surface Antigen in HB e Antigen-Seronegative Patients. Clinical Gastroenterology and Hepatology. 17(1). 172–181.e1. 25 indexed citations
13.
Yau, Thomas, Riccardo Lencioni, Wattana Sukeepaisarnjaroen, et al.. (2016). A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research. 23(10). 2405–2413. 58 indexed citations
14.
Liu, Chen‐Hua, Cheng‐Chao Liang, Chun‐Jen Liu, et al.. (2015). Comparison of Abbott RealTime HCV Genotype II with Versant Line Probe Assay 2.0 for Hepatitis C Virus Genotyping. Journal of Clinical Microbiology. 53(5). 1754–1757. 59 indexed citations
15.
Chen, Pei‐Jer, et al.. (2015). Evaluation of the protective effects of curcuminoid (curcumin and bisdemethoxycurcumin)-loaded liposomes against bone turnover in a cell-based model of osteoarthritis. SHILAP Revista de lepidopterología. 10 indexed citations
16.
Tseng, Tai‐Chung, Chun‐Jen Liu, Hung‐Chih Yang, et al.. (2014). Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers. Gut. 64(2). 292–302. 84 indexed citations
17.
Tai, Wei‐Tien, Chung-Wai Shiau, Yao-Li Chen, et al.. (2013). SC-60, a Dimer-Based Sorafenib Derivative, Shows a Better Anti–Hepatocellular Carcinoma Effect than Sorafenib in a Preclinical Hepatocellular Carcinoma Model. Molecular Cancer Therapeutics. 13(1). 27–36. 7 indexed citations
18.
Afdhal, Nezam H., Geoffrey Dusheiko, Edoardo G. Giannini, et al.. (2011). FINAL RESULTS OF ENABLE 1, A PHASE 3, MULTICENTER STUDY OF ELTROMBOPAG AS AN ADJUNCT FOR ANTIVIRAL TREATMENT OF HEPATITIS C VIRUS-RELATED CHRONIC LIVER DISEASE ASSOCIATED WITH THROMBOCYTOPENIA. UCL Discovery (University College London). 12 indexed citations
19.
Yang, Hwai‐I, Morris Sherman, Jun Su, et al.. (2010). Nomograms for Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection. Journal of Clinical Oncology. 28(14). 2437–2444. 210 indexed citations
20.
Chen, Pei‐Jer, et al.. (1995). MGM volume 59 issue 395 Cover and Front matter. Mineralogical Magazine. 59(395). f1–f1. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stefan Zeuzem Breakdown of academic impact, for papers by Christian Bréchot Breakdown of academic impact, for papers by Dieter Häussinger Breakdown of academic impact, for papers by Kazuaki Chayama Breakdown of academic impact, for papers by Zachary Goodman Breakdown of academic impact, for papers by Christian Trautwein Breakdown of academic impact, for papers by William M. Lee Breakdown of academic impact, for papers by Frank Tacke Breakdown of academic impact, for papers by Masao Omata Breakdown of academic impact, for papers by Jacob George
Rankless by CCL
2026